Canurta Journal

Optimization of Cannflavin Production in Germinated Hemp Seeds: Insights into Metabolomic and Antioxidant Profiles

Medical Marijuana for ALS Symptom Management: Potential Benefits and Risks in Disease Progression

Cannabistilbene I as a Potential Therapeutic for Cardiac Hypertrophy: Modulating Key Enzymes and Metabolic Pathways

3-Minute Pitch at ACT Canada Consortium: Advancing ALS Treatment with CNR-401

FDA Drug Approvals in 2023: Insights into Trends and Molecule Types

The Gut-Brain Axis: Exploring the Impact of Gut Microbiota-Derived Phenolic Compounds on Neurocognition

Cannflavin-C Counters Heart Enlargement Triggered by Angiotensin II: Impact on Enzymes and Fatty Acid Metabolism

Canurta Therapeutics Secures First US Patent for Novel Bioactive Polyphenol Extraction Process

Exploring Cannabis Pharmacology: Beyond THC and CBD

AI: Transforming the Future of Nutraceuticals

The Protective Role of Cannflavins A and B Against Cell Death in Human Skin Cells

Investigation of cannflavins from Cannabis sativa as potential anti-SARS-CoV-2 agents

The Antiatherogenic Potential of Flavonoids in Cardiovascular Health

Cannflavin A Displays Both a Hormetic and Neuroprotective Profile Against Alzheimer's Disease Progression

Preclinical Research with a First-in-Class ALS Therapy Formulation

Reflecting on the ALS Drug Development Summit in Boston

The Comprehensive Neurotherapeutic Potential of Cannabis sativa

Chemistry and Activities of Cannflavins

Innovating Plant Flavonoid Production

Canurta Inc. Unveils Strategic Reorganization & Rebranding: Introducing Canurta Therapeutics and Canurta Naturals